Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H21N2O5S.K |
| Molecular Weight | 416.533 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CC[C@H](OC1=CC=CC=C1)C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O
InChI
InChIKey=ULBKMFLWMIGVOJ-JOPMDFRVSA-M
InChI=1S/C18H22N2O5S.K/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20;/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24);/q;+1/p-1/t11-,12+,13-,16+;/m0./s1
| Molecular Formula | C18H21N2O5S |
| Molecular Weight | 377.435 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6421744Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2158301 | https://www.ncbi.nlm.nih.gov/pubmed/13909124 | https://www.ncbi.nlm.nih.gov/pubmed/13863272
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6421744
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2158301 | https://www.ncbi.nlm.nih.gov/pubmed/13909124 | https://www.ncbi.nlm.nih.gov/pubmed/13863272
Levopropylcillin – is a penicillin derivative, L-enantiomer of antibiotic Propicillin. Levopropylcillin properties are similar to benzylpenicillin particularly used in streptococcal infections, not resistant to penicillinase. Levopropylcillin is acid resistant and can be used orally as the potassium salt.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4114 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2158301 |
|||
Target ID: GO:0031506 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | propicillin Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6421744
The patients received 1 Mega unit (0.7 g) propicillin orally as oblong tablets one or two hours before surgery.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1952836
Mixed continuous cultures of periodontal bacteria were obtained from the enrichment of subgingival plaque by using human serum as a growth medium. After stabilization of the culture by
15 volume changes, a single dose of propicillin, which was dissolved in 0.5 ml of water to give a final concentration of 1 mg/liter in the vessel, was added to the experimental culture. Two subsequent doses of 1 mg/liter were given at 24-h intervals, that is, after 2.4 volume changes, during which the concentration of propicillin in the vessel dropped by dilution until it was approximately 10o of the original value. One day (24 h) after the last addition, a sample was taken from the culture for microbiological analyses. Higher concentrations of propicillin were tested in experimental cultures that were obtained by transferring 2.5 ml from the control culture to a new vessel and then adding serum to a final volume of 5 ml. After batch growth for 24 h, the culture was switched to continuous growth, and after stabilization for 5 to 10 volume changes, the culture was exposed to 5, 10, or 50 mg of propicillin per liter added in a single dose. The addition of antibiotic was repeated after 24 h. Samples for microbiological analyses were taken 24 h after the second addition of propicillin.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:25:45 GMT 2025
by
admin
on
Mon Mar 31 18:25:45 GMT 2025
|
| Record UNII |
2IY8ZC06FM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23674237
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
PRIMARY | |||
|
C83882
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
PRIMARY | |||
|
2IY8ZC06FM
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL2111179
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
PRIMARY | |||
|
300000055212
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
PRIMARY | |||
|
4803-44-5
Created by
admin on Mon Mar 31 18:25:45 GMT 2025 , Edited by admin on Mon Mar 31 18:25:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |